Research programme: undecaprenyl diphosphate synthase inhibitors - Merck

Drug Profile

Research programme: undecaprenyl diphosphate synthase inhibitors - Merck

Alternative Names: Undecaprenyl diphosphate synthase inhibitors research programme - Merck; UppS inhibitors research programme - Merck

Latest Information Update: 08 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cubist Pharmaceuticals
  • Class
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Anthrax

Most Recent Events

  • 20 Sep 2004 No development reported - Preclinical for Anthrax in USA (unspecified route)
  • 01 Aug 2002 Preclinical trials in Anthrax in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top